FIXX Stock Overview
Homology Medicines, Inc., a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Homology Medicines, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$16.82 |
| 52 Week High | US$26.64 |
| 52 Week Low | US$8.24 |
| Beta | -0.11 |
| 1 Month Change | 8.42% |
| 3 Month Change | 65.32% |
| 1 Year Change | -6.53% |
| 3 Year Change | -89.93% |
| 5 Year Change | -96.83% |
| Change since IPO | -94.99% |
Recent News & Updates
Recent updates
Homology Medicines (NASDAQ:FIXX) Will Have To Spend Its Cash Wisely
Nov 16
Homology Medicines appoints new CEO, chairperson
Sep 06Homology announces peer-reviewed preclinical data publication on its AAVHSC16 capsid
Jul 05Here's Why We're Watching Homology Medicines' (NASDAQ:FIXX) Cash Burn Situation
Jan 28Homology Medicines: In Vivo Gene Therapy Platform With Delayed Lead Trial Coming Back Online
Oct 22We Think Homology Medicines (NASDAQ:FIXX) Can Afford To Drive Business Growth
Sep 18Growth Investors: Industry Analysts Just Upgraded Their Homology Medicines, Inc. (NASDAQ:FIXX) Revenue Forecasts By 20%
Aug 14Industry Analysts Just Made A Sizeable Upgrade To Their Homology Medicines, Inc. (NASDAQ:FIXX) Revenue Forecasts
May 22Homology Medicines (FIXX) Investor Presentation - Slideshow
May 05Homology Medicines (NASDAQ:FIXX) Is In A Good Position To Deliver On Growth Plans
Apr 17Are Institutions Heavily Invested In Homology Medicines, Inc.'s (NASDAQ:FIXX) Shares?
Mar 13Homology Medicines' (NASDAQ:FIXX) Stock Price Has Reduced 25% In The Past Year
Feb 03Shareholder Returns
| FIXX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 3.8% | -4.7% | -3.7% |
| 1Y | -6.5% | -2.7% | 20.2% |
Return vs Industry: FIXX underperformed the US Biotechs industry which returned 10.2% over the past year.
Return vs Market: FIXX underperformed the US Market which returned 29.8% over the past year.
Price Volatility
| FIXX volatility | |
|---|---|
| FIXX Average Weekly Movement | 7.4% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: FIXX's share price has been volatile over the past 3 months.
Volatility Over Time: FIXX's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 7 | n/a | www.homologymedicines.com |
Homology Medicines, Inc., a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases in the United States. The company offers proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a nuclease-free gene editing mobility, gene therapy or for various genetic disorders. Its earlier stage product candidates comprising HMI-202, an investigational gene therapy which completed IND-enabling studies for the treatment of metachromatic leukodystrophy; and HMI-104 which completed IND-enabling studies.
Homology Medicines, Inc. Fundamentals Summary
| FIXX fundamental statistics | |
|---|---|
| Market cap | US$54.34m |
| Earnings (TTM) | -US$112.96m |
| Revenue (TTM) | US$1.16m |
47.0x
P/S Ratio-0.5x
P/E RatioIs FIXX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| FIXX income statement (TTM) | |
|---|---|
| Revenue | US$1.16m |
| Cost of Revenue | US$62.00m |
| Gross Profit | -US$60.85m |
| Other Expenses | US$52.12m |
| Earnings | -US$112.96m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -34.98 |
| Gross Margin | -5,263.49% |
| Net Profit Margin | -9,771.71% |
| Debt/Equity Ratio | 0% |
How did FIXX perform over the long term?
See historical performance and comparison